Tekla Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Tekla Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$6.29M	Hold	154,269	–	–	0.25%	77
2023 Q1	$5.75M	Hold	154,269	–	–	0.22%	75
2022 Q4	$5.38M	Hold	154,269	–	–	0.2%	76
2022 Q3	$8.63M	Buy	154,269 +96,089	+165%	+$5.96M	0.35%	58
2022 Q2	$3.01M	Hold	58,180	–	–	0.12%	103
2022 Q1	$4.23M	Hold	58,180	–	–	0.15%	101
2021 Q4	$6.88M	Hold	58,180	–	–	0.22%	86
2021 Q3	$7.8M	Hold	58,180	–	–	0.25%	85
2021 Q2	$9.42M	Buy	58,180 +5,000	+9%	+$389K	0.31%	85
2021 Q1	$4.27M	Buy	+53,180	New	+$3.57M	0.15%	125
2020 Q3	–	Sell	-55,050	Closed	-$1.16M	–	215
2020 Q2	$1.16M	Hold	55,050	–	–	0.04%	189
2020 Q1	$673K	Hold	55,050	–	–	0.03%	188
2019 Q4	$808K	Hold	55,050	–	–	0.03%	182
2019 Q3	$735K	Sell	55,050 -95,240	-63%	-$1.52M	0.03%	169
2019 Q2	$2.46M	Hold	150,290	–	–	0.1%	124
2019 Q1	$2.57M	Hold	150,290	–	–	0.1%	122
2018 Q4	$2.05M	Buy	150,290 +81,619	+119%	+$1.52M	0.09%	128
2018 Q3	$1.97M	Sell	68,671 -98,710	-59%	-$2.87M	0.07%	156
2018 Q2	$4.58M	Hold	167,381	–	–	0.17%	97
2018 Q1	$3.53M	Buy	+167,381	New	+$4.12M	0.14%	108
2017 Q3	–	Sell	-28,000	Closed	-$448K	–	157
2017 Q2	$448K	Sell	28,000 -43,842	-61%	-$613K	0.02%	138
2017 Q1	$1.01M	Hold	71,842	–	–	0.04%	126
2016 Q4	$942K	Hold	71,842	–	–	0.04%	130
2016 Q3	$1.22M	Sell	71,842 -15,000	-17%	-$290K	0.05%	130
2016 Q2	$1.85M	Buy	+86,842	New	+$2.31M	0.08%	132

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Tekla Capital Management's NTLA Position: Q2 2023 in Review

Tekla Capital Management held its Intellia Therapeutics (NTLA) position steady in Q2 2023 at 154,269 shares worth $6.29M. The position accounts for 0.25% of the portfolio, ranked #77.

Tekla Capital Management first reported a position in NTLA in Q2 2016 and has held it in 25 quarters since. The position peaked at $9.42M in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

Tekla Capital Management held 154,269 shares of Intellia Therapeutics worth $6.29M as of Q2 2023.
Tekla Capital Management left its Intellia Therapeutics share count unchanged in Q2 2023.
Intellia Therapeutics made up 0.25% of Tekla Capital Management's portfolio in Q2 2023, its #77 holding.
Tekla Capital Management first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 25 quarters since.
Tekla Capital Management's Intellia Therapeutics position peaked at $9.42M in Q2 2021.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.